About InCarda

Committed to developing transformative therapies for cardiac conditions.

InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.

The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

We are a team of highly-experienced, passionate teammates who have a strong track record of development.  We are also supported by a world-class group of experts and advisors.

Our Mission & Vision

Our mission is to develop transformative therapies by pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. Our vision is to enable a new paradigm for acute cardiac care, empowering patients to take control, feel better sooner and improve their health.

Our Core Values

Our Novel Approach

Our approach is designed to reduce the risks and timelines normally associated with drug development.
Our model is based on the following three tenets:


Known Heart Conditions with High Unmet Need

InCarda’s products target well-known heart diseases & conditions.

Known Drugs


Using approved drugs via inhalation is a unique paradigm for treating heart conditions which potentially reduces development risk.

New Delivery


Our optimized, inhaled products target regions of the heart where cardiac conditions arise, potentially increasing therapy success while reducing large life-time exposure to chronic medication.

For more information about InCarda: